Nashwa Kabil

852 total citations
19 papers, 540 citations indexed

About

Nashwa Kabil is a scholar working on Oncology, Molecular Biology and Reproductive Medicine. According to data from OpenAlex, Nashwa Kabil has authored 19 papers receiving a total of 540 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 8 papers in Molecular Biology and 8 papers in Reproductive Medicine. Recurrent topics in Nashwa Kabil's work include Ovarian cancer diagnosis and treatment (8 papers), PARP inhibition in cancer therapy (7 papers) and BRCA gene mutations in cancer (6 papers). Nashwa Kabil is often cited by papers focused on Ovarian cancer diagnosis and treatment (8 papers), PARP inhibition in cancer therapy (7 papers) and BRCA gene mutations in cancer (6 papers). Nashwa Kabil collaborates with scholars based in United States, Egypt and Türkiye. Nashwa Kabil's co-authors include Bülent Özpolat, Recep Bayraktar, Gabriel Lopez‐Berestein, Nermin Kahraman, Hamada A. Mokhlis, George A. Călin, Pınar Kanlikilicer, David M. O’Malley, Cristina Ivan and Kathleen N. Moore and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Nashwa Kabil

17 papers receiving 535 citations

Peers

Countries citing papers authored by Nashwa Kabil

Since Specialization

Citations

This map shows the geographic impact of Nashwa Kabil's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nashwa Kabil with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nashwa Kabil more than expected).

Fields of papers citing papers by Nashwa Kabil

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nashwa Kabil. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nashwa Kabil. The network helps show where Nashwa Kabil may publish in the future.

Co-authorship network of co-authors of Nashwa Kabil

This figure shows the co-authorship network connecting the top 25 collaborators of Nashwa Kabil. A scholar is included among the top collaborators of Nashwa Kabil based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nashwa Kabil. Nashwa Kabil is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	eEF2K is a poor prognostic factor and novel molecular target in pancreatic cancer: regulating tumor growth and progression via the tumor microenvironment 2025 ·Cell Death and Disease ·Didem Karakaş, Ahmed A. Ashour, Hamada A. Mokhlis, Nermin Kahraman, Recep Bayraktar, (unknown), Nashwa Kabil, Mümin Alper Erdoğan, (unknown), Engı̇n Ulukaya, (unknown)	0
2	Olaparib as treatment for platinum‐sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency: Phase 2 LIGHT study final overall survival analysis 2025 ·Cancer ·Ying L. Liu, Cara Mathews, Fiona Simpkins, Karen A. Cadoo, Diane Provencher, Colleen McCormick, Adam C. ElNaggar, Alon D. Altman, Lucy Gilbert, Destin Black, Nashwa Kabil, (unknown), Alan Barnicle, (unknown), Carol Aghajanian	1
3	The Role of Curcumin in Preventing Naturally Occurring Leiomyoma in the Galline Model 2024 ·Pharmaceuticals ·Kazım Şahin, Cemal Orhan, Mehmet Tuzcu, Nurhan Şahin, İbrahim H. Özercan, Nashwa Kabil, Ömer Küçük, Bülent Özpolat	1
4	PARP Inhibitors in Ovarian Cancer: A Review 2023 ·Targeted Oncology ·David M. O’Malley, Thomas C. Krivak, Nashwa Kabil, (unknown), Kathleen N. Moore	76
5	Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysis 2022 ·Gynecologic Oncology ·Karen A. Cadoo, Fiona Simpkins, Cara Mathews, Ying L. Liu, Diane Provencher, Colleen McCormick, Adam C. ElNaggar, Alon D. Altman, Lucy Gilbert, Destin Black, Nashwa Kabil, James Bennett, (unknown), Carol Aghajanian	18
6	ncRNA therapy with miRNA-22-3p suppresses the growth of triple-negative breast cancer 2021 ·Molecular Therapy — Nucleic Acids ·Ayşegül Görür, Recep Bayraktar, Cristina Ivan, Hamada A. Mokhlis, Emine Bayraktar, Nermin Kahraman, Didem Karakaş, (unknown), Nashwa Kabil, Pınar Kanlikilicer, Burcu Aslan, Lülüfer Tamer, Zhihui Wang, Vittorio Cristini, Gabriel Lopez‐Berestein, George A. Călin, Bülent Özpolat	36
7	Olaparib treatment in patients with platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: secondary efficacy results from the phase II LIGHT study 2021 ·Gynecologic Oncology ·Karen A. Cadoo, Fiona Simpkins, Cara Mathews, Ying Liu, Diane Provencher, Colleen McCormick, Adam C. ElNaggar, Nashwa Kabil, James P. Bennett, Hong Yu, (unknown), Carol Aghajanian	2
8	Olaparib treatment (Tx) in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSR OC) by BRCA mutation (BRCAm) and homologous recombination deficiency (HRD) status: Overall survival (OS) results from the phase II LIGHT study. 2021 ·Journal of Clinical Oncology ·Cara Mathews, Fiona Simpkins, Karen A. Cadoo, Ying L. Liu, Diane Provencher, Colleen McCormick, Adam C. ElNaggar, Alon D. Altman, Lucy Gilbert, Destin Black, Nashwa Kabil, James Bennett, (unknown), (unknown), Carol Aghajanian	2
9	Olaparib treatment in patients with platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: secondary safety results from the phase II LIGHT study 2021 ·Gynecologic Oncology ·Karen A. Cadoo, Fiona Simpkins, Cara Mathews, Alon D. Altman, Lucy Gilbert, Ying Liu, Destin Black, (unknown), Nashwa Kabil, James A. Bennett, Hong Yu, Carol Aghajanian	3
10	GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma 2020 ·Cellular Signalling ·Amr Ahmed El‐Arabey, Merve Denizli, Pınar Kanlikilicer, Recep Bayraktar, Cristina Ivan, Mohammed H. Rashed, Nashwa Kabil, Bülent Özpolat, George A. Calin, (unknown), Adel R. A. Abd‐Allah, Anil K. Sood, Gabriel Lopez‐Berestein	99
11	Olaparib treatment in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) by BRCA mutation (BRCAm) and homologous recombination deficiency (HRD) status: Phase II LIGHT study. 2020 ·Journal of Clinical Oncology ·Karen A. Cadoo, Fiona Simpkins, Cara Mathews, Nashwa Kabil, James Bennett, Carol Aghajanian	12
12	Genistein Prevents Development of Spontaneous Ovarian Cancer and Inhibits Tumor Growth in Hen Model 2019 ·Cancer Prevention Research ·Kazım Şahin, (unknown), Birdal Bilir, Cemal Orhan, Mehmet Tuzcu, Nurhan Şahin, İbrahim H. Özercan, Nashwa Kabil, Bülent Özpolat, Ömer Küçük	36
13	Therapeutic targeting of the PI4K2A/PKR lysosome network is critical for misfolded protein clearance and survival in cancer cells 2019 ·Oncogene ·Apar Pataer, Bülent Özpolat, (unknown), Neil R. Cashman, Steven S. Plotkin, Charles E. Samuel, Steven H. Lin, Nashwa Kabil, Jing Wang, Mourad Majidi, Bingliang Fang, Jack A. Roth, Ara A. Vaporciyan, Ignacio I. Wistuba, Mien‐Chie Hung, Stephen G. Swisher	21
14	Dual Suppressive Effect of miR-34a on the FOXM1/eEF2-Kinase Axis Regulates Triple-Negative Breast Cancer Growth and Invasion 2018 ·Clinical Cancer Research ·Recep Bayraktar, Cristina Ivan, Emine Bayraktar, Pınar Kanlikilicer, Nashwa Kabil, Nermin Kahraman, Hamada A. Mokhlis, Didem Karakaş, Cristian Rodriguez‐Aguayo, Ahmet Arslan, Jianting Sheng, Stephen T.C. Wong, Gabriel Lopez‐Berestein, George A. Călin, Bülent Özpolat	74
15	Elongation factor-2 kinase (eEF-2K) expression is associated with poor patient survival and promotes proliferation, invasion and tumor growth of lung cancer 2018 ·Lung Cancer ·Ahmet Bircan, Nilgün Gürbüz, Apar Pataer, Ayşe Caner, Nermin Kahraman, Emine Bayraktar, Recep Bayraktar, Mümin Alper Erdoğan, Nashwa Kabil, Bülent Özpolat	37
16	The Modulatory Role of MicroRNA-873 in the Progression of KRAS-Driven Cancers 2018 ·Molecular Therapy — Nucleic Acids ·Hamada A. Mokhlis, Recep Bayraktar, Nashwa Kabil, Ayşe Caner, Nermin Kahraman, Cristian Rodriguez‐Aguayo, Érika Pereira Zambalde, Jianting Sheng, Kübra Karagoz, Pınar Kanlikilicer, (unknown), Tamer M. Abdelghany, Ahmed A. Ashour, Stephen T.C. Wong, Michael L. Gatza, George A. Călin, Gabriel Lopez‐Berestein, Bülent Özpolat	28
17	Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer 2018 ·Breast Cancer Research and Treatment ·Nashwa Kabil, Recep Bayraktar, Nermin Kahraman, Hamada A. Mokhlis, George A. Călin, Gabriel Lopez‐Berestein, Bülent Özpolat	67
18	Abstract 504: miR-484 acts as an “oncomiR” in triple negative breast cancer cells to promote tumor growth and progression by targeting HOXA5 2018 ·Cancer Research ·Nashwa Kabil, Recep Bayraktar, Cristina Ivan, Nermin Kahraman, Hamada A. Mokhlis, George A. Calin, Gabriel Lopez‐Berestein, Bülent Özpolat	3
19	Effect of ghrelin on chronic liver injury and fibrogenesis in male rats: Possible role of nitric oxide 2013 ·Peptides ·Nashwa Kabil, (unknown), (unknown), (unknown)	24

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact